BRPI0917417A2 - mnétodos de tratar deficiência cognitiva - Google Patents

mnétodos de tratar deficiência cognitiva

Info

Publication number
BRPI0917417A2
BRPI0917417A2 BRPI0917417A BRPI0917417A BRPI0917417A2 BR PI0917417 A2 BRPI0917417 A2 BR PI0917417A2 BR PI0917417 A BRPI0917417 A BR PI0917417A BR PI0917417 A BRPI0917417 A BR PI0917417A BR PI0917417 A2 BRPI0917417 A2 BR PI0917417A2
Authority
BR
Brazil
Prior art keywords
methods
cognitive impairment
treating cognitive
treating
impairment
Prior art date
Application number
BRPI0917417A
Other languages
English (en)
Inventor
Gary W Arendash
Huntington Potter
Steven Bennett
Timothy Boyd
Original Assignee
Univ South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Florida filed Critical Univ South Florida
Publication of BRPI0917417A2 publication Critical patent/BRPI0917417A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0917417A 2008-08-05 2009-08-04 mnétodos de tratar deficiência cognitiva BRPI0917417A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8635108P 2008-08-05 2008-08-05
PCT/US2009/052742 WO2010017224A2 (en) 2008-08-05 2009-08-04 Methods of treating cognitive impairment

Publications (1)

Publication Number Publication Date
BRPI0917417A2 true BRPI0917417A2 (pt) 2015-12-01

Family

ID=41664174

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917417A BRPI0917417A2 (pt) 2008-08-05 2009-08-04 mnétodos de tratar deficiência cognitiva

Country Status (10)

Country Link
US (4) US20110142795A1 (pt)
EP (1) EP2320934A4 (pt)
JP (1) JP2011530520A (pt)
KR (1) KR20110068993A (pt)
CN (1) CN102215860A (pt)
BR (1) BRPI0917417A2 (pt)
CA (1) CA2733126A1 (pt)
MX (1) MX2011001486A (pt)
RU (1) RU2011108560A (pt)
WO (1) WO2010017224A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102215860A (zh) * 2008-08-05 2011-10-12 南佛罗里达大学 治疗认知损害的方法
US9132168B2 (en) 2008-08-05 2015-09-15 University Of South Florida Methods of treating cognitive impairment
US9238689B2 (en) 2011-07-15 2016-01-19 Morpho Sys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
AU2012285875B2 (en) 2011-07-18 2016-11-10 Morphosys Ag Use of c-Fms antagonists
AU2014253090B2 (en) 2013-04-12 2018-10-25 Morphosys Ag Antibodies targeting M-CSF
WO2015020523A1 (en) 2013-08-07 2015-02-12 Stichting Vu-Vumc Biomarkers for early diagnosis of alzheimer's disease
WO2022174104A1 (en) * 2021-02-12 2022-08-18 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for personalized treatment of neurodegenerative conditions or side effects thereof
WO2022182954A1 (en) * 2021-02-26 2022-09-01 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treating type 2 diabetes using granulocyte-macrophage colony-stimulating factor (gm-csf)
US20240415930A1 (en) * 2021-08-04 2024-12-19 Washington University Compositions and methods for enhancing brain perfusion
WO2025262249A1 (en) * 2024-06-21 2025-12-26 Universidad De Navarra Prevention of cognitive-decline disorders derived from radiotherapy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034322A (en) * 1983-01-17 1991-07-23 Monsanto Company Chimeric genes suitable for expression in plant cells
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) * 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) * 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US5167649A (en) * 1988-08-22 1992-12-01 Zook Gerald P Drug delivery system for the removal of dermal lesions
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5106739A (en) * 1989-04-18 1992-04-21 Calgene, Inc. CaMv 355 enhanced mannopine synthase promoter and method for using same
JPH04198134A (ja) * 1990-11-28 1992-07-17 Eisai Co Ltd 老人性痴呆症の治療・予防剤
UA48104C2 (uk) * 1991-10-04 2002-08-15 Новартіс Аг Фрагмент днк, який містить послідовність,що кодує інсектицидний протеїн, оптимізовану для кукурудзи,фрагмент днк, який забезпечує направлену бажану для серцевини стебла експресію зв'язаного з нею структурного гена в рослині, фрагмент днк, який забезпечує специфічну для пилку експресію зв`язаного з нею структурного гена в рослині, рекомбінантна молекула днк, спосіб одержання оптимізованої для кукурудзи кодуючої послідовності інсектицидного протеїну, спосіб захисту рослин кукурудзи щонайменше від однієї комахи-шкідника
PT749472E (pt) * 1994-03-07 2004-11-30 Immunex Corp Kits de cultura extracorporal e transplantacao de celulas
JPH08113535A (ja) * 1994-10-13 1996-05-07 Sumitomo Pharmaceut Co Ltd 神経細胞の変性または死滅抑制剤
JP2002535247A (ja) * 1998-11-26 2002-10-22 ペンタファルム アクチェンゲゼルシャフト 輸送系複合体
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
AU2001250912B2 (en) * 2000-03-21 2007-01-04 Curagen Corporation VEGF-modulated genes and methods employing them
CA2425610A1 (en) * 2000-10-13 2002-04-18 University Of Lausanne Intracellular delivery of biological effectors by novel transporter peptide sequences
US7033597B2 (en) * 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
JP4055397B2 (ja) * 2001-11-05 2008-03-05 信越化学工業株式会社 含フッ素有機ケイ素化合物
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
KR20050019732A (ko) * 2002-06-07 2005-03-03 코티컬 피티와이 리미티드 대식세포 유주 저지 인자의 생물학적 활성 또는사이토카인을 억제하는 나프탈렌 유도체
US20060275294A1 (en) * 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
AU2005306894B2 (en) * 2004-11-05 2011-11-24 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
EP2377884A1 (en) * 2005-05-10 2011-10-19 Neoloch Aps Neuritogenic peptides
US8398972B2 (en) * 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
WO2009029508A1 (en) 2007-08-28 2009-03-05 Johnnie B. Byrd, Sr. Alzheimer's Center And Research Institute, Inc. Intracranial catheter and methods of use
US9132168B2 (en) * 2008-08-05 2015-09-15 University Of South Florida Methods of treating cognitive impairment
CN102215860A (zh) * 2008-08-05 2011-10-12 南佛罗里达大学 治疗认知损害的方法

Also Published As

Publication number Publication date
WO2010017224A2 (en) 2010-02-11
WO2010017224A3 (en) 2010-05-06
US9682124B2 (en) 2017-06-20
EP2320934A4 (en) 2012-08-01
CN102215860A (zh) 2011-10-12
US11896647B2 (en) 2024-02-13
US20210106654A1 (en) 2021-04-15
JP2011530520A (ja) 2011-12-22
US20140255337A1 (en) 2014-09-11
KR20110068993A (ko) 2011-06-22
MX2011001486A (es) 2011-05-02
CA2733126A1 (en) 2010-02-11
RU2011108560A (ru) 2012-09-10
US20170189490A1 (en) 2017-07-06
EP2320934A2 (en) 2011-05-18
US20110142795A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
BRPI0910854A2 (pt) métodos de tratamento
BRPI0908276A2 (pt) Métodos de tratar dor inflamatória
BRPI0924069A2 (pt) métodos de diagnosticar e tratar disfagia
BRPI0921482A2 (pt) tratamento de leucemia linfoblástica aguda
PL3476371T3 (pl) Urządzenie do leczenia gerd
BRPI0910259A2 (pt) métodos de tratamento de inflamação
EP2301812A4 (en) PARKING AIDS AND PARKING PROCEDURE
BRPI0912317A2 (pt) método de autenticação
BRPI1007477A2 (pt) método, e, composição de tratamento de poço
BRPI0811265A2 (pt) Tratamento de sinucleinopatias
EP2504011A4 (en) METHOD FOR TREATING EASY COGNITIVE IMPAIRMENT
EP2294227A4 (en) CONCENTRATION TEST
EP2316062A4 (en) Modifying conversation windows
PL2435825T3 (pl) Sposoby leczenia chorób
BRPI0916222A2 (pt) método de tratamento e equipamento de tratamento de águas residuais
PT2370225E (pt) Redução da formação de acrilamida
BRPI1008744A2 (pt) hidrotratamento de caboidratos
BR112012003956A2 (pt) método de tratar água residual
BRPI0916079A2 (pt) tratamento de água marinha residual
BR112013012072A2 (pt) derivados, composições de benzodiazepina e métodos para o tratamento de danos cognitivos
EP2320934A4 (en) PROCESS FOR TREATING COGNITIVE IMPAIRMENT
DK2554171T3 (da) Fremgangsmåde til behandling af sygdomme
BRPI0912043A2 (pt) métodos de tratamento de doença associada à cinesina meiótica
DE112010004214A5 (de) Zugkraft-Abstandhalteranordnung, Verfahren zum Herstellen und Anwendung
BRPI1014394A2 (pt) método de tratamento de vidro

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.